Funding Impact: Accelerated vector manufacturing capabilities
Successful Exit: Acquired by Pfizer in August 2016
CureDuchenne Ventures was formed in 2014 after the successful exit from an equity investment in Prosensa (acquired by BioMarin Pharmaceuticals for $680M).
Our robust pipeline of therapies comes from a diverse array of cutting edge technologies used to treat all aspects of Duchenne. CureDuchenne Ventures’ early funding helps Duchenne science attract future investments made by VC firms, biotech companies and pharmaceutical companies.
CureDuchenne Ventures, LLC is the investment arm of CureDuchenne, a national nonprofit dedicated to curing Duchenne muscular dystrophy, the most common and lethal form of muscular dystrophy.
CureDuchenne Ventures supports Duchenne research by using philanthropic donations to encourage development of new Duchenne drugs. Through an impact financing model we can provide both grant funding to academic groups, as well as equity financing to biotech and pharmaceutical companies.
Fund the totality of Duchenne’s expression to identify novel biological targets, pharmaceutical assets, and research programs that exhibit the most potential to advance rapidly to clinical trial proof of concept studies.
Treat the whole disease by sponsoring a variety of approaches that are needed to treat Duchenne’s many genetic variants, and because of the complexity of the human genome, a variety of approaches are needed to develop the most effective treatments. Without the protein dystrophin, inflammation will lead to the infiltration of fat, scar, or fibrous tissue in muscle. The most life threatening damage can be to the heart and diaphragm muscles, resulting in cardiac and respiratory failure as the leading causes of death for those with Duchenne. In addition, Duchenne boys suffer from a loss of independence resulting from fibrosis leading to loss of ambulation and reduced mobility. Consequently, in addition to supporting research aimed at replacing the missing dystrophin protein; CureDuchenne Ventures has backed projects for heart failure, respiratory failure, anti-inflammatory, and anti-fibrotic treatments.
Develop new biomarkers, statistical models, and clinical endpoints to facilitate drug development through financing and strategic partnerships with leading experts, scientists and companies in the industry.